Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Donovan Joanne M. | CMO | May 02 '24 | Sale | 18.91 | 3,682 | 69,627 | 19,897 | May 03 06:27 PM | | KOCH KEVIN | President and CEO | May 02 '24 | Sale | 18.91 | 3,152 | 59,604 | 14,478 | May 03 06:26 PM | | Carruthers R Michael | Chief Financial Officer | May 02 '24 | Sale | 18.91 | 2,157 | 40,789 | 35,230 | May 03 06:30 PM | | MOORE JOHN R | General Counsel | May 02 '24 | Sale | 18.91 | 1,956 | 36,988 | 3,252 | May 03 06:31 PM | | Derakhshan Behrad | Chief Business Officer | May 02 '24 | Sale | 18.91 | 1,718 | 32,487 | 13,422 | May 03 06:29 PM | | Russell Alan J | Chief Scientific Officer | May 02 '24 | Sale | 18.91 | 1,576 | 29,802 | 7,238 | May 03 06:28 PM | | Russell Alan J | Chief Scientific Officer | May 01 '24 | Option Exercise | 0.00 | 5,208 | 0 | 8,814 | May 03 06:28 PM | | Donovan Joanne M. | CMO | May 01 '24 | Option Exercise | 0.00 | 10,417 | 0 | 23,579 | May 03 06:27 PM | | KOCH KEVIN | President and CEO | May 01 '24 | Option Exercise | 0.00 | 10,417 | 0 | 17,630 | May 03 06:26 PM | | Derakhshan Behrad | Chief Business Officer | May 01 '24 | Option Exercise | 0.00 | 5,208 | 0 | 15,140 | May 03 06:29 PM | | Carruthers R Michael | Chief Financial Officer | May 01 '24 | Option Exercise | 0.00 | 5,208 | 0 | 37,387 | May 03 06:30 PM | | MOORE JOHN R | General Counsel | May 01 '24 | Option Exercise | 0.00 | 5,208 | 0 | 5,208 | May 03 06:31 PM | | MOORE JOHN R | General Counsel | Feb 09 '24 | Option Exercise | 1.93 | 8,029 | 15,496 | 8,029 | Feb 09 05:43 PM | | Derakhshan Behrad | Chief Business Officer | Feb 09 '24 | Option Exercise | 1.93 | 4,800 | 9,264 | 11,820 | Feb 09 05:42 PM | | MOORE JOHN R | General Counsel | Feb 09 '24 | Sale | 20.01 | 8,029 | 160,657 | 0 | Feb 09 05:43 PM | | Derakhshan Behrad | Chief Business Officer | Feb 09 '24 | Sale | 20.04 | 4,800 | 96,209 | 7,020 | Feb 09 05:42 PM | | Derakhshan Behrad | Chief Business Officer | Feb 08 '24 | Option Exercise | 1.93 | 4,600 | 8,878 | 11,620 | Feb 09 05:42 PM | | MOORE JOHN R | General Counsel | Feb 08 '24 | Option Exercise | 1.93 | 3,813 | 7,359 | 3,813 | Feb 09 05:43 PM | | Derakhshan Behrad | Chief Business Officer | Feb 08 '24 | Sale | 20.01 | 4,600 | 92,049 | 7,020 | Feb 09 05:42 PM | | MOORE JOHN R | General Counsel | Feb 08 '24 | Sale | 20.01 | 3,813 | 76,285 | 0 | Feb 09 05:43 PM | | MOORE JOHN R | General Counsel | Feb 07 '24 | Option Exercise | 1.93 | 17,993 | 34,726 | 17,993 | Feb 09 05:43 PM | | Derakhshan Behrad | Chief Business Officer | Feb 07 '24 | Option Exercise | 1.93 | 600 | 1,158 | 7,620 | Feb 09 05:42 PM | | MOORE JOHN R | General Counsel | Feb 07 '24 | Sale | 20.00 | 17,993 | 359,864 | 0 | Feb 09 05:43 PM | | Derakhshan Behrad | Chief Business Officer | Feb 07 '24 | Sale | 20.00 | 600 | 12,000 | 7,020 | Feb 09 05:42 PM | | Carruthers R Michael | Chief Financial Officer | Jan 23 '24 | Option Exercise | 1.93 | 90,000 | 173,700 | 119,024 | Jan 25 04:46 PM | | ORBIMED ADVISORS LLC | Director | Jan 23 '24 | Buy | 11.00 | 454,545 | 4,999,995 | 14,436,497 | Jan 25 04:28 PM | | Thompson Peter A. | Director | Jan 23 '24 | Buy | 11.00 | 454,545 | 4,999,995 | 14,436,497 | Jan 25 04:32 PM | | Carruthers R Michael | Chief Financial Officer | Jan 23 '24 | Sale | 15.78 | 90,000 | 1,419,759 | 29,024 | Jan 25 04:46 PM | | MOORE JOHN R | General Counsel | Dec 27 '23 | Sale | 10.50 | 8,497 | 89,218 | 0 | Dec 28 04:39 PM | | Fox Jonathan C | Director | Dec 26 '23 | Buy | 9.30 | 10,857 | 100,958 | 10,857 | Dec 28 04:39 PM | | Russell Alan J | Chief Scientific Officer | Dec 26 '23 | Sale | 9.33 | 172,585 | 1,610,097 | 3,606 | Dec 28 04:38 PM | | Carruthers R Michael | Chief Financial Officer | Jun 22 '23 | Option Exercise | 0.71 | 10,000 | 7,100 | 29,024 | Jun 26 04:28 PM |
|
